Ameena El-Bibany

Ameena was previously a Partner at ARTIS Ventures and sat on the Boards of Range Biotechnologies and Activ Surgical and was an investor in Inceptive Nucleics, among other companies. She has received recognition by Fortune as one of 11 VCs behind the hottest health tech deals and by the San Francisco Business Times as a 40 Under 40 honoree. Prior to joining ARTIS, she spent 5 years in early stage venture capital as a Partner at Rising Tide VC, where she built and led the firm’s health and bio investment practice and invested in companies including Precision NanoSystems (acquired by Danaher), Apama Medical (acquired by Boston Scientific), Evonetix, Exo Imaging, Loop Genomics (acquired by Element Biosciences), Aspect Biosystems, Atia Vision and others. Focusing on the intersection of science and technology, she has invested in and worked with companies spanning personalized medicine, synthetic biology, computational biology and more. She is passionate about bridging academia and industry to create lasting impact. Ameena began her career in R&D, working at Novozymes, a world leader in bio innovation, developing synthetic biology approaches to increase yields through industrial scale up. She is a recipient of multiple competitive grants funded by the National Science Foundation for research done at the California Academy of Sciences and the Bermuda Institute of Ocean Sciences, as well as an awardee of the National Science Foundation Graduate Research Fellowship Program. She has conducted research across DNA damage and repair in longevity, microbiome diversity, and stem cell engineering. Ameena holds a BS in Genetics from the University of California Davis.